Ellele Sampling Device is being used in PREDI-Lynch Trial

Ellele Health will be participating in PREDI-Endo, a study nested in PREDI-Lynch, a major pan-European project funded through the Horizon Grant programme, focused on improving early cancer detection for individuals with Lynch syndrome.

Lynch syndrome is the most common inherited cancer predisposition syndrome (CPS), yet it has historically been underfunded and underserved, resulting in significant inequalities in access to effective surveillance and early diagnosis. PREDI-Lynch brings together leading European clinicians, researchers, biotechnology companies, and patient advocates to address this unmet need through a coordinated, practice-changing approach. PREDI-Lynch will use an innovative clinical study design to evaluate multiple non-invasive, liquid biopsy-based technologies across the three most common Lynch syndrome–associated cancer types. The programme also includes a comprehensive assessment of socio-economic and ethical considerations, ensuring that resulting solutions meet patients’ and societal needs, and are compatible with different healthcare systems.

Dr. Neil Ryan, RCOG Subspecialty Trainee in Gynaecological Oncology at the Royal Infirmary of Edinburgh, CSO/NES Clinical Lecturer at the University of Edinburgh and CMO of Ellele Health, is leading the PREDI-Endo study. The study will evaluate the diagnostic performance of the Ellele Sampling Device for early endometrial cancer detection versus standard surveillance including endometrial biopsy, transvaginal ultrasound and blood test.

Participation in PREDI-Endo represents an important step in Ellele Health’s mission to provide a minimally invasive alternative sampling method while collecting a high-quality sample that supports state-of-the-art diagnostic assays.

To find out more about PREDI-Lynch, visit the project website: https://predi-lynch.eu/